Certara (Certara) EBIT per Share : $-0.25 (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Certara EBIT per Share?

Certara's EBIT per Share for the three months ended in Mar. 2024 was $0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.25.

During the past 12 months, the average EBIT per Share Growth Rate of Certara was -107.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Certara's EBIT per Share or its related term are showing as below:

During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Certara was 16.80% per year. The lowest was 16.80% per year. And the median was 16.80% per year.

CERT's 3-Year EBIT Growth Rate is not ranked ^*
in the Healthcare Providers & Services industry.
Industry Median: 8
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Certara's EBIT for the three months ended in Mar. 2024 was $0.3 Mil.

Certara EBIT per Share Historical Data

The historical data trend for Certara's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Certara EBIT per Share Chart

Certara Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

0.12

-0.19

0.09

0.23

-0.20

Certara Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															0.05	0.09	-0.30	-0.04	-

Certara EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Certara's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-32.227	/	158.936
=	-0.20

Certara's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	0.317	/	159.524
=	0.00

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.25

Certara (NAS:CERT) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Certara EBIT per Share Related Terms

Thank you for viewing the detailed overview of Certara's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Certara (Certara) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Certara Inc (NAS:CERT) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Overlook Center, Suite 101, Princeton, NJ, USA, 08540

Website

https://www.certara.com

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The group has a business presence in the United States, EMEA, and other regions, of which a majority of revenue is derived from the United States.

Executives

Richard M. Traynor	officer: See Remarks	1114 AVENUE OF THE AMERICAS, 45TH FLOOR, NEW YORK NY 10036
Leif E Pedersen	officer: President, Software	10188 TELESIS COURT, SUITE 100, SAN DIEGO CA 92121
Eran Broshy	director	C/O VENTIV HEALTH, 200 COTTONTAIL LN. VANTAGE COURT N., SOMERSET NJ 08873
Patrick F Smith	officer: PRESIDENT, INTEGRATED DRUG DEV	C/O CERTARA, INC., 100 OVERLOOK CENTER, SUITE 101, PRINCETON NJ 08540
John E Gallagher	officer: CHIEF FINANCIAL OFFICER	BECTON, DICKINSON AND COMPANY, FRANKLIN LAKES NJ 07417
Arsenal Saturn Holdings Lp	10 percent owner	C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Jeffrey B. Kovach	10 percent owner	C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Arsenal Capital Partners Iii-b Lp	10 percent owner	100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Terrence M. Mullen	10 percent owner	C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Eqt Avatar Parent L.p.	10 percent owner	100 OVERLOOK CENTER, SUITE 101, PRINCETON NJ 08540
Arsenal Capital Investment Iii Lp	10 percent owner	C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Arsenal Capital Investment Vi Lp	10 percent owner	C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Arsenal Capital Partners Iii Lp	10 percent owner	100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
David Spaight	director	100 OVERLOOK CENTER, SUITE 101, PRINCETON NJ 08540
Mason P Slaine	director	2777 SUMMER STREET, SUITE 209, STAMFORD CT 06905